文献速递瓣膜病与结构性心脏病

无症状重度主动脉瓣狭窄:早期手术与保守治疗的随机对照试验(AVATAR)

Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial.
PubMed 文献 · Circulation · 2021-11-13

AVATAR 试验在 7 个欧洲国家 9 个中心纳入 157 例无症状重度主动脉瓣狭窄且左心室功能正常、运动试验阴性的患者,随机分入早期 SAVR 组或保守治疗组。中位随访 32 个月,早期手术组主要复合终点(全因死亡、急性心肌梗死、卒中或计划外心衰住院)发生率显著低于保守组(HR 0.46,95%CI 0.23-0.90,P=0.02)。

要点

  • 无症状重度 AS 且左室功能正常患者,早期 SAVR 可降低主要复合终点风险。
  • 早期手术组 92.3% 接受 SAVR,手术死亡率为 1.4%。
  • 次要终点(全因死亡、心衰住院、大出血、血栓栓塞)无统计学差异。

核心结论

  • 在无症状重度 AS 患者中,与保守治疗相比,早期 SAVR 降低了全因死亡、急性心肌梗死、卒中或计划外心衰住院的复合终点发生率。

研究设计与样本

  • AVATAR 为研究者发起的国际前瞻性随机对照试验,在 7 个欧洲国家 9 个中心进行。
  • 2015 年 6 月至 2020 年 9 月共随机 157 例患者(平均年龄 67 岁,57% 男性),早期手术组 78 例,保守治疗组 79 例。
  • 纳入标准为无症状重度 AS(瓣口面积 ≤1 cm² 且主动脉射流速度 >4 m/s 或平均跨瓣压差 ≥40 mm Hg)、左心室功能正常且运动试验阴性。
  • 试验设计为事件驱动,预设最少 35 个事件;主要终点为全因死亡、急性心肌梗死、卒中或计划外心衰住院的复合终点。

主要发现

  • 中位随访 32 个月(早期手术组 28 个月,保守治疗组 35 个月),共发生 39 个事件,早期手术组 13 个,保守治疗组 26 个。
  • 意向性分析显示,早期手术组主要复合终点发生率显著低于保守治疗组(HR 0.46,95%CI 0.23-0.90,P=0.02)。
  • 早期手术组 72 例(92.3%)接受 SAVR,手术死亡率为 1.4%。
  • 次要终点包括全因死亡、首次心衰住院、大出血或血栓栓塞并发症无统计学差异,但趋势与主要终点一致。

关键数值与推荐

  • 重度 AS 定义:瓣口面积 ≤1 cm² 且主动脉射流速度 >4 m/s 或平均跨瓣压差 ≥40 mm Hg。
  • 主要复合终点 HR 0.46(95%CI 0.23-0.90),P=0.02。
  • 早期手术组 SAVR 比例 92.3%,手术死亡率 1.4%。

临床怎么用

  • 对于无症状重度 AS 且左心室功能正常、运动试验阴性的患者,可考虑早期 SAVR 以降低复合终点风险。
  • 治疗决策需结合个体情况和指南,本试验为早期手术提供了初步随机对照证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical aortic valve replacement (SAVR) represents a class I indication in symptomatic patients with severe aortic stenosis (AS). However, indications for early SAVR in asymptomatic patients with severe AS and normal left ventricular function remain debated. METHODS: The AVATAR trial (Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis) is an investigator-initiated international prospective randomized controlled trial that evaluated the safety and efficacy of early SAVR in the treatment of asymptomatic patients with severe AS, according to common criteria (valve area ≤1 cm2 with aortic jet velocity >4 m/s or a mean transaortic gradient ≥40 mm Hg), and with normal left ventricular function. Negative exercise testing was mandatory for inclusion. The primary hypothesis was that early SAVR would reduce the primary composite end point of all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure compared with a conservative strategy according to guidelines. The trial was designed as event-driven to reach a minimum of 35 prespecified events. The study was performed in 9 centers in 7 European countries. RESULTS: Between June 2015 and September 2020, 157 patients (mean age, 67 years; 57% men) were randomly allocated to early surgery (n=78) or conservative treatment (n=79). Follow-up was completed in May 2021. Overall median follow-up was 32 months: 28 months in the early surgery group and 35 months in the conservative treatment group. There was a total of 39 events, 13 in early surgery and 26 in the conservative treatment group. In the early surgery group, 72 patients (92.3%) underwent SAVR with operative mortality of 1.4%. In an intention-to-treat analysis, patients randomized to early surgery had a significantly lower incidence of primary composite end point than those in the conservative arm (hazard ratio, 0.46 [95% CI, 0.23-0.90]; P=0.02). There was no statistical difference in secondary end points, including all-cause mortality, first heart failure hospitalizations, major bleeding, or thromboembolic complications, but trends were consistent with the primary outcome. CONCLUSIONS: In asymptomatic patients with severe AS, early surgery reduced a primary composite of all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure compared with conservative treatment. This randomized trial provides preliminary support for early SAVR once AS becomes severe, regardless of symptoms. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02436655.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Banovic M, Putnik S, Penicka M, et al. Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. Circulation. 2021. PMID: 34779220. doi:10.1161/CIRCULATIONAHA.121.057639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。